In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
13 authors.
Grace UwaseDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Priya LuthraDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Olivia A VogelDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Jyoti BatraGladstone Institute of Data Science and Biotechnology, J. David Gladstone Institutes, San Francisco, CA, 94158, USA.
Bruno A La RosaNEIDL, Boston University, Chobanian & Avedisian School of Medicine, Boston, MA, 02118 USA.
Kathleen C F SheehanDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.ORCID 0000-0002-3357-8285 Oam KhatavkarDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Jacqueline E PaytonDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.ORCID 0000-0001-8832-3661 Robert A DaveyNEIDL, Boston University, Chobanian & Avedisian School of Medicine, Boston, MA, 02118 USA.ORCID 0000-0001-9168-2892 Nevan J KroganGladstone Institute of Data Science and Biotechnology, J. David Gladstone Institutes, San Francisco, CA, 94158, USA.ORCID 0000-0003-4902-337X Christopher F BaslerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0003-4195-425X Daisy W LeungDepartment of Medicine, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.ORCID 0000-0002-7189-9557 Gaya K AmarasingheDepartment of Pathology and Immunology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.ORCID 0000-0002-0418-9707 Funding
X-ray Screening and Rapid Structure DeterminationP50GM082250 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KROGAN, NEVAN J · 2007 to 2018
$48.8MThe role of Listeria cyclic-di-AMP during infection and immunityP01AI063302 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI PORTNOY, DANIEL A · 2004 to 2025
$45.5MVirus CoreU19AI106754 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BENNER, CHRISTOPHER W · 2013 to 2017
$26.0MTherapeutics Targeting Filoviral interferon-antagonist and replication functionsU19AI109664 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BASLER, CHRISTOPHER F · 2014 to 2018
$15.8MMolecular mechanisms of immune dysregulation by filoviral interferon U19AI109945 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BASLER, CHRISTOPHER F · 2014 to 2018
$9.5MDiscovery of novel, ubiquitin-regulated mechanisms of TB control by macrophagesR01AI120694 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COX, JEFFERY S, KROGAN, NEVAN J · 2015 to 2019
$3.3MNIAID NIH HHS P01 AI063302NIAID NIH HHS R01 AI120694NIAID NIH HHS U19 AI106754NIAID NIH HHS U19 AI109664NIAID NIH HHS U19 AI109945NIGMS NIH HHS P50 GM082250
6 · The paper itselfAbstract
Ebola virus (EBOV) is a non-segmented, negative-sense virus (NNSV) with a single-stranded RNA genome. EBOV encodes for a limited number of proteins and thus depends on host factors to facilitate viral replication and pathogenesis. Of the virus-encoded proteins, multifunctional EBOV VP35 (eVP35) is necessary for host immune evasion and viral RNA synthesis. Previous proteomics studies identified an interaction between eVP35 and the host E3 ubiquitin ligase Mindbomb 2 (MIB2). Here, we show how a previously uncharacterized NNLNS motif (residues 201-205) within eVP35 serves as a binding site for MIB2. This motif is critical for eVP35-dependent inhibition of MIB2-mediated IFN induction. It is also important for EBOV RNA synthesis as MIB2 binding to eVP35 inhibited EBOV minigenome activity. Altogether, these findings highlight the importance of the eVP35 protein and the role of host factors in EBOV infection.
Indexed as
biophysical studiesfilovirushost-pathogen interactionsvirusesVP35
Identifiers
PMID40777377
PMCPMC12330714
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390